Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Clin Exp Neuropsychol ; 26(6): 759-78, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15370374

ABSTRACT

We examined the interrater (IRR) of clinical ratings of neuropsychological (NP) impairment and neurocognitive diagnoses in HIV. Thirty participants with advanced HIV-infection who were enrolled in a multicenter HIV brain banking research project underwent comprehensive NP and neuromedical evaluations. Using a standardized system of guidelines, neuropsychologists from six participating sites independently assigned clinical ratings of NP impairment, as well as multilevel diagnoses reflecting the inferred etiology of the impairments and their effects on everyday functioning. Findings indicated excellent IRR in rating the presence and severity of NP impairment, but overall modest IRR for neurocognitive diagnoses. Not surprisingly, most diagnostic disagreements concerned the etiology of impairments in persons with medical and neuropsychiatric risk factors in addition to HIV.


Subject(s)
Brain/physiopathology , Cognition Disorders/etiology , HIV Infections/complications , Neuropsychological Tests , Reproducibility of Results , Adult , Confounding Factors, Epidemiologic , Decision Making/physiology , Demography , Female , HIV Infections/epidemiology , Humans , Male , Neuropsychological Tests/statistics & numerical data , Observer Variation , Risk Factors , Severity of Illness Index
2.
Mov Disord ; 17(5): 1031-5, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12360554

ABSTRACT

Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug-induced hallucinations in Parkinson's disease (PD). We conducted a double-blind, placebo-controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5-10 mg/day to effect) in 30 PD patients with drug-induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and 11 on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low-dose olanzapine did not significantly improve hallucinations but did worsen motor function.


Subject(s)
Antipsychotic Agents/therapeutic use , Dopamine Agonists/therapeutic use , Hallucinations/chemically induced , Hallucinations/drug therapy , Parkinson Disease/drug therapy , Pirenzepine/analogs & derivatives , Pirenzepine/therapeutic use , Aged , Benzodiazepines , Cognition Disorders/chemically induced , Cognition Disorders/diagnosis , Dopamine Agonists/adverse effects , Double-Blind Method , Female , Hallucinations/diagnosis , Humans , Interview, Psychological , Male , Neuropsychological Tests , Olanzapine
3.
Mov Disord ; 17(1): 91-7, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11835444

ABSTRACT

Vascular parkinsonism (VP) is a poorly defined entity which has clinical, and perhaps pathological, overlap with other diagnoses. Although classical VP involves lesions of the basal ganglia, the majority of cases actually show diffuse subcortical white matter changes (SCWMC) on imaging. The exact pathologies of these white matter changes are debated and likely heterogeneous, but are generally thought to represent areas of chronic or recurrent partial ischemia. Cerebrospinal fluid (CSF) drainage is the treatment for NPH and has been reported to improve symptoms in some patients with idiopathic NPH and associated SCWMC. To determine whether historical, clinical, or radiographic factors predict improvement in VP patients after CSF drainage, we removed 35-40 ml of CSF via lumbar punctures (LP) from 40 patients and compared responders with nonresponders for a variety of demographics, clinical features, and blindly interpreted magnetic resonance images (MRI). Fifteen patients (37.5%) reported "significant and irrefutable" gait improvement after LP. Twelve (30.0%) reported no effect and 13 (32.5%) reported mild or very transient improvement. Timed gait in a subset of patients improved (P < 0.05) immediately after LP. Clinically, improvement after CSF removal was predicted by any positive response to levodopa (P < 0.001), the lack of vertical gaze palsies (P < 0.05), the lack of a pure freezing gait (P < 0.05), and the lack of hypotensive episodes (P < 0.05). Blinded MRI interpretation did not find features which clearly predicted response. Some patients diagnosed with VP improved after LP. Clinically, these patients tended to resemble idiopathic PD, whereas nonresponders more closely resembled progressive supranuclear palsy (PSP). These results warrant further investigation and also raise the possibility of testing CSF drainage in patients with idiopathic PD complicated by SCWMC.


Subject(s)
Basal Ganglia Cerebrovascular Disease/complications , Movement Disorders/etiology , Movement Disorders/therapy , Parkinsonian Disorders/complications , Spinal Puncture/methods , Aged , Brain/pathology , Female , Humans , Hydrocephalus, Normal Pressure/diagnosis , Hydrocephalus, Normal Pressure/therapy , Magnetic Resonance Imaging , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...